Nebivolol

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318353

CAS#: 118457-14-0

Description: Nebivolol is a β1 receptor blocker with nitric oxide-potentiating vasodilatory effect used in treatment of hypertension and, in Europe, also for left ventricular failure. It is highly cardioselective under certain circumstances.


Price and Availability

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2021-01-19. Prices are subject to change without notice.

Nebivolol is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 318353
Name: Nebivolol
CAS#: 118457-14-0
Chemical Formula: C22H25F2NO4
Exact Mass: 405.1752
Molecular Weight: 405.435
Elemental Analysis: C, 65.17; H, 6.22; F, 9.37; N, 3.45; O, 15.78


Synonym: R 065824; R065824; R-065824; Nebivolol; Nobiten; Vasoxen

IUPAC/Chemical Name: 1-((R)-6-fluorochroman-2-yl)-2-(((R)-2-((R)-6-fluorochroman-2-yl)-2-hydroxyethyl)amino)ethanol

InChi Key: KOHIRBRYDXPAMZ-JJTQDJFQSA-N

InChi Code: InChI=1S/C22H25F2NO4/c23-15-3-7-19-13(9-15)1-5-21(28-19)17(26)11-25-12-18(27)22-6-2-14-10-16(24)4-8-20(14)29-22/h3-4,7-10,17-18,21-22,25-27H,1-2,5-6,11-12H2/t17-,18?,21-,22-/m1/s1

SMILES Code: O[C@H](CNCC([C@H]1CCC2=CC(F)=CC=C2O1)O)[C@H]3CCC4=CC(F)=CC=C4O3


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001


References

1: Sander GE, Giles TD. Nebivolol and valsartan as a fixed-dose combination for the treatment of hypertension. Expert Opin Pharmacother. 2015 Apr;16(5):763-70. doi: 10.1517/14656566.2015.1020790. Review. PubMed PMID: 25747524.

2: Howlett JG. Nebivolol: vasodilator properties and evidence for relevance in treatment of cardiovascular disease. Can J Cardiol. 2014 May;30(5 Suppl):S29-37. doi: 10.1016/j.cjca.2014.03.003. Epub 2014 Mar 5. Review. PubMed PMID: 24750980.

3: Varagic J, Punzi H, Ferrario CM. Clinical utility of fixed-dose combinations in hypertension: evidence for the potential of nebivolol/valsartan. Integr Blood Press Control. 2014 Nov 26;7:61-70. doi: 10.2147/IBPC.S50954. eCollection 2014. Review. PubMed PMID: 25473311; PubMed Central PMCID: PMC4251532.

4: Patrascu N. Diastolic heart failure in hypertension: possible preventive benefits of nebivolol beyond lowering blood pressure. Maedica (Buchar). 2013 Sep;8(3):285-9. Review. PubMed PMID: 24371501; PubMed Central PMCID: PMC3869121.

5: DiNicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O'Keefe JH. Meta-analysis of carvedilol versus beta 1 selective beta-blockers (atenolol, bisoprolol, metoprolol, and nebivolol). Am J Cardiol. 2013 Mar 1;111(5):765-9. doi: 10.1016/j.amjcard.2012.11.031. Epub 2013 Jan 4. Review. PubMed PMID: 23290925.

6: Toblli JE, DiGennaro F, Giani JF, Dominici FP. Nebivolol: impact on cardiac and endothelial function and clinical utility. Vasc Health Risk Manag. 2012;8:151-60. doi: 10.2147/VHRM.S20669. Epub 2012 Mar 13. Review. PubMed PMID: 22454559; PubMed Central PMCID: PMC3310359.

7: Gao Y, Vanhoutte PM. Nebivolol: an endothelium-friendly selective β1-adrenoceptor blocker. J Cardiovasc Pharmacol. 2012 Jan;59(1):16-21. doi: 10.1097/FJC.0b013e3182073e27. Review. PubMed PMID: 21283024.

8: Riva N, Lip GY. Nebivolol for the treatment of heart failure. Expert Opin Investig Drugs. 2011 Dec;20(12):1733-46. doi: 10.1517/13543784.2011.625011. Epub 2011 Oct 8. Review. PubMed PMID: 21980961.

9: Del Sindaco D, Tinti MD, Monzo L, Pulignano G. Clinical and economic aspects of the use of nebivolol in the treatment of elderly patients with heart failure. Clin Interv Aging. 2010 Dec 3;5:381-93. doi: 10.2147/CIA.S4482. Review. PubMed PMID: 21152240; PubMed Central PMCID: PMC2998246.

10: Giles TD. The role of vasodilating beta-blockers in patients with complicated hypertension: focus on nebivolol. Am J Med. 2010 Jul;123(7 Suppl 1):S16-20. doi: 10.1016/j.amjmed.2010.04.014. Review. PubMed PMID: 20609694.

11: Bakris GL, Basile JN, Giles TD, Taylor AA. The role of nitric oxide in improving endothelial function and cardiovascular health: focus on nebivolol. Am J Med. 2010 Jul;123(7 Suppl 1):S2-8. doi: 10.1016/j.amjmed.2010.04.012. Review. PubMed PMID: 20609695.

12: Gauthier C, Trochu JN. [Nebivolol: the first vasodilatory beta-blocker with a beta3-adrenergic agonist activity]. Ann Cardiol Angeiol (Paris). 2010 Jun;59(3):155-9. doi: 10.1016/j.ancard.2010.05.003. Review. French. PubMed PMID: 20620250.

13: Lipsic E, van Veldhuisen DJ. Nebivolol in chronic heart failure: current evidence and future perspectives. Expert Opin Pharmacother. 2010 Apr;11(6):983-92. doi: 10.1517/14656561003694650. Review. PubMed PMID: 20307222.

14: Münzel T, Gori T. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol. 2009 Oct 13;54(16):1491-9. doi: 10.1016/j.jacc.2009.05.066. Review. PubMed PMID: 19815121.

15: Dal Negro R. Pulmonary effects of nebivolol. Ther Adv Cardiovasc Dis. 2009 Aug;3(4):329-34. doi: 10.1177/1753944709339968. Review. PubMed PMID: 19638367.

16: Mason RP, Giles TD, Sowers JR. Evolving mechanisms of action of beta blockers: focus on nebivolol. J Cardiovasc Pharmacol. 2009 Aug;54(2):123-8. doi: 10.1097/FJC.0b013e3181ad207b. Review. PubMed PMID: 19528811.

17: Maffei A, Lembo G. Nitric oxide mechanisms of nebivolol. Ther Adv Cardiovasc Dis. 2009 Aug;3(4):317-27. doi: 10.1177/1753944709104496. Epub 2009 May 14. Review. PubMed PMID: 19443516.

18: Baldwin CM, Keam SJ. Nebivolol: in the treatment of hypertension in the US. Am J Cardiovasc Drugs. 2009;9(4):253-60. doi: 10.2165/1120274-000000000-00000. Review. PubMed PMID: 19655820.

19: Agabiti-Rosei E, Porteri E, Rizzoni D. Arterial stiffness, hypertension, and rational use of nebivolol. Vasc Health Risk Manag. 2009;5(1):353-60. Review. PubMed PMID: 19475771; PubMed Central PMCID: PMC2686253.

20: O'Malley P. Nebivolol: a new third-generation beta-blocker agent: implications for Clinical Nurse Specialist Practice. Clin Nurse Spec. 2008 May-Jun;22(3):126-8. doi: 10.1097/01.NUR.0000311691.85038.02. Review. PubMed PMID: 18438160.